We previously reported that (Z)-2-{4-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]benzyloxyimino}-2-(4-phenoxyphenyl)acetic acid (3) showed potent glucose and lipid lowering effects in genetically obese and diabetic mice, KKA y . This compound also showed transcriptional activity for peroxisome proliferator-activated receptor (PPAR)-g g. We expanded on the structure-activity relationships of oxyiminoalkanoic acid derivatives based on this transcriptional activity (in vitro). Insertion of a carbon chain between the imino carbon and the carboxyl moiety of (Z)-2-{4-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]benzyloxyimino}-2-phenylacetic acid (2) resulted in a marked increase in transcriptional activity at PPARg g. In vivo potencies of synthesized compounds, which showed strong functional activity at PPARg g, were tested using KKA y mice. Among these compounds, (E)-4-{4-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]benzyloxyimino}-4-phenylbutyric acid (27) exhibited marked glucose and lipid lowering activity while showing no significant body weight gain. Compound (27) (TAK-559) showed favorable pharmacokinetic properties with good absorption and duration, and was considered as an attractive candidate for further evaluation.
Insulin resistance is a fundamental abnormality of type 2 diabetes and impaired glucose tolerance (IGT).
2) Type 2 diabetes is defined by a high plasma glucose level, which leads to a gradual progression of complications, including neuropathy, nephropathy, retinopathy, arteriosclerosis, and coronary artery disease. [3] [4] [5] [6] Treatment usually consists of a regimen of diet and exercise, and oral antihyperglycemic agents such as sulfonylureas, biguanides, and a-glucosidase inhibitors. Insulin is also used in severe cases. 7) Recent clinical studies suggested that intensive control of HbA 1c levels reduced complications for both type 1 and type 2 diabetes, and revealed the importance of drugs for reducing plasma glucose levels. [8] [9] [10] [11] However, drugs can cause problems including compliance, hypoglycemia, and obesity. 12, 13) Thus, new antidiabetic drugs that have improved compliance and reduced side effects are still required.
Recently, 2,4-thiazolidinedione analogs, including pioglitazone (1) 14) (Chart 1), have been launched as antidiabetic agents. [15] [16] [17] There are a number of groups that endeavor to produce new antidiabetic agents in this area. [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] Although the mechanisms of insulin resistance and action of 2,4-thiazolidinedione analogs and related compounds are not yet fully understood, a number of reports suggest that pioglitazone reduces insulin resistance. For example, treatment with pioglitazone increased the insulin action for the decrease of hepatic glucose production and for the increase of peripheral glucose utilization in Wistar fatty rats. 30, 31) In addition, pioglitazone improved the defects of the insulin-stimulated tyrosine phosphorylation of insulin receptors and insulin receptor substrate 1 (IRS-1) and phosphatidylinositol (PI) 3-kinase activation in skeletal muscle of the fatty rats. 32) These effects were not observed in Wistar lean rats. It was also suggested that tumor necrosis factor-a (TNF-a) plays a key role in the systemic insulin resistance of type 2 diabetes. 33) Pioglitazone reduced the TNF-a level in muscle which was accompanied by an improvement of metabolic abnormalities in Wistar fatty rats. 34) A recent study suggests that antidiabetic thiazolidinediones interact with a family of nuclear receptors known as the peroxisome proliferator-activated receptor (PPAR)-g. 35) It was also observed that the extent of the activation of PPARg in vitro mirrored antihyperglycemic activity in diabetic ob/ob mice. 36) There might be a correlation between TNF-a and PPARg.
Thiazolidinediones such as pioglitazone, rosiglitazone, and troglitazone have made a great contribution to therapy for type 2 diabetes. However, weight gain has been reported as a side effect of these drugs. 13) Thus, improvement of the thiazolidinedione class of antidiabetic agents is still worth pursuing.
In the previous paper, we reported the discovery of two novel oxyiminoacetic acid derivatives as potent glucose and lipid lowering agents, (Z)-2-{4-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]benzyloxyimino}-2-phenylacetic acid (2) and (Z)-2-{4-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]-benzyloxyimino}-2-(4-phenoxyphenyl)acetic acid (3) (Fig.  1) . 1) These oxyiminoacetic acids showed transcriptional activity for PPARg, indicating that the mechanisms of action of oxyiminoacetic acid derivatives involve PPARg, at least in part. 36 ) So, we were interested in finding more potent PPARg agonists. We synthesized a new series of oxyiminoalkanoic acids (structure A, Fig. 1 ) to investigate the effect of linkage between the imino carbon and carboxy group based on PPARg transcriptional activity. Compounds, which showed potent PPARg activity, were tested using KKA y mice 37) to evaluate not only antidiabetic activity but also the effect on as a mixture of isomers (ca. 5 : 1). The major isomer of 17 (or 8 synthesized by method B in Chart 2) is presumed to have E configuration, considering a report described that reactions of alkyl phenyl ketones with methoxyamine yielded oximes having the hydroxy trans to phenyl. 38) (Z)-Isomers of 17 were removed by column chromatography. Only (E)-isomers were used for the next reaction. Alkylation of (E)-17 with appropriate chloromethylheterocycles followed by saponification with aqueous LiOH yielded oxyiminoalkanoic acids (19) .
The methods employed to prepare the intermediates (7 and 11) in Charts 2 and 3 are shown in Chart 4. Friedel-Crafts acylation of substituted benzenes with acid chlorides gave acylated benzenes (11) which were treated with hydroxylamine to provide oximes (7) as a mixture of isomers. These isomers were easily separated by column chromatography. The major isomer of oximes is also presumed to have E configuration considering a report. 39) This assumption is supported by X-ray analysis of 27 (data not shown). Compound (27) , prepared from major isomer of methyl 4-(hydroxyimino)-4-phenylbutyrate (7a), was identified to have E configuration (the alkoxy of imino group trans to phenyl).
Pyridine analogues (11h-j) were prepared via a four-step procedure 40) (Chart 5). Carbonyldiimidazole (CDI) was used to condense pyridinecarboxylic acids (20) and lithium enolate of tert-butyl acetate to give pyridyl b-keto esters. Alkylation of the b-keto esters with ethyl bromoacetate followed by removal of the tert-butyl group and decarboxylation under acidic conditions gave the desired pyridyl g-ketoesters (11h-j).
a,a-Dimethylester (11k) was synthesized from 21 41) (Chart 6). Reduction of 21 with lithium aluminum hydride gave alcohol (22) . Methanesulfonylation of 22 and subsequent reaction with sodium iodide gave iodoalkane (23) .
Treatment of 23 with lithium enolate of methyl isobutyrate and subsequent deprotection under acidic conditions provided a,a-dimethylester (11k).
Compounds (2, 26) were condensed with amino acid ethyl ether to give 24 and 25, which were saponificated with aqueous LiOH to give 42 and 43, respectively (Chart 7).
The analytical data of all oxyiminoalkanoic acids (26-57) synthesized are shown in Tables 1 and 2 .
Results and Discussion
All compounds synthesized were evaluated for the ability to activate PPARg in a transactivation assay in CHO-K1 cells. The results are shown in Tables 1 and 2 . First of all, the effect of inserting an alkyl chain between the imino carbon and the carboxyl moiety of 2 was scrutinized. Surprisingly, a marked increase in activity was observed on insertion of alkyl chains of various lengths. The insertion of one, two, or three carbons at that position in compound (2) resulted in a 30 to 80-fold increase in functional activity (26, 27, 30) . Compounds with a four-(31, EC 50 ϭ2.5 nM) or five-(34, EC 50 ϭ3.9 nM) carbon insertion were 750-and 490-fold more active than 2, respectively. Further extension of the carbon chain decreased potency (35, 36) . Thus, an important relationship was found between the length of the inserted carbon chain and the functional activation of PPARg. Straight chains were preferable to branched (44 vs. 31), fixed (45 vs. 27), and amide-containing (42, 43 vs. 31) chains as linkages at that position. Next, the effect of the substitution pattern on the central benzene ring was examined. Para-and meta-isomeric compounds were almost equi-potent (27 vs. 28; 31 vs. 33), and were more potent than the ortho-analogue (27, 28 vs. 29) . Exchange of the phenyl group adjacent to the imino carbon with the 3-pyridyl or 4-pyridyl group resulted in a decrease in functional activity (40, 41 vs. 27) , although the 2-pyridyl derivative kept potency (39 vs. 27 ). This result suggested that a hydrophobic substituent was preferred at that position. The methyl group at the 5-position of the oxazole ring played an important role in the activity (46 vs. 27). This result is similar to the case of in vivo antihyperglycemic activity of thiazolidinedione analogs.
42) The 5-methyl-1,3-oxazole structure was preferable to other azoles (47-50 vs. 27). Substitution of the phenyl moiety on the oxazole ring at the 2-position of the 2-furyl or 2-thienyl moiety maintained or improved potency (51, 52 vs. 27; 56, 57 vs. 31). Extension of the methoxy spacer between the oxazole ring and the central benzene ring did not increase potency (55 vs. 27). E-Isomer seems to be more potent at least in vitro assay, though there is only one example (32 vs. 31).
Next, the antidiabetic activities of oxyiminoalkanoic acids were evaluated using KKA y mice. 37) Test compounds were selected based on transcriptional activity for PPARg (EC 50 Ͻ0.1 mM). The results are shown in Table 3 . A number of these compounds significantly reduced plasma glucose levels even at a dosage of 0.001% in the diet (but not 28, 30, 33, 38, 44). It is noteworthy that compound (27) showed potent glucose and lipid lowering activities while showing no significant body weight gain compared with the control. These profiles were preferable for antidiabetic agents. Considering the report that describes the structure-activity relationship for PPARg agonist activity in vitro accurately predicts the in vivo glucose lowering activity in diabetic mice, 36) it is not clear why compounds (28, 30, 33, 38, 44) , which possessed potent PPARg transcriptional activity, were not as effective for glucose lowering as 27. A possible interpretation of this fact is that these compounds might not be absorbed sufficiently or might be metabolized rapidly when administered orally to KKA y mice. Anyway, further investigation of ineffective compounds seemed not to be worth carrying out.
Compound (27) was investigated further. Table 4 shows glucose and lipid lowering activities of 27 and pioglitazone hydrochloride in KKA y mice. Compound (27) exhibited a 9-fold increase in glucose lowering activity and a 50-fold increase in lipid lowering activity compared to pioglitazone hydrochloride.
Pharmacokinetic analysis (Table 5) suggested that com- pound (27) has favorable pharmacokinetic characteristics. The AUC 0-24 h (261.36Ϯ18.52 mg · h/ml/p.o. and 30.57Ϯ2.11 mg · h/ml/i.v.) and bioavailability (85.5Ϯ8.4%) were high enough, which suggests that the system is well exposed to compound (27) .
In summary, we showed that a new series of oxyiminoalkanoic acid derivatives had strong transcriptional activity for PPARg and potent antidiabetic effects in genetically obese and diabetic KKA y mice. Compound (27) , which had strong glucose and lipid lowering activity while showing no significant body weight gain, exhibited a 9-fold increase in glucose lowering activity and a 50-fold increase in lipid lowering activity compared to pioglitazone hydrochloride. Compound (27, TAK-559) possessed very good pharmacokinetic characteristics and selected as a candidate for further evaluation.
Experimental
Biological Procedures. (a) PPARg g-Retinoid X Receptor a a (RXRa a) Heterodimer Transactivation Assay The full-length human PPARg1, full-length human RXRa and PPAR responsive luciferase reporter were stably expressed in CHO-K1 cells. These cells were cultured in HAM F12 medium (NISSUI SEIYAKU) containing 10% fetal bovine serum (Life Technologies, Inc., U.S.A.), inoculated into a 96-well white plate (Corning Coaster Corporation, U.S.A.) at a density of 2ϫ10 4 cells/well, and cultured in a carbonate gas incubator at 37°C overnight. The white plate was washed with PBS (Phosphate-buffered saline), and 90 ml of HAM F12 medium containing 0.1% fatty acid-free bovine serum albumin (BSA) and 10 ml of test substance were added. The plate was then cultured in the carbonate gas incubator at 37°C for 48 h. The medium was removed, 40 ml of PICAGENE 7.5 (Wako Pure Chemical Ind. Ltd.) was added, and after stirring, luciferase activity was determined using Lumistar (BMG Labtechnologies GmBH, Germany). Induction magnitude was calculated based on the luciferase activity of each test substance with the luciferase activity in the non-treatment group assigned a value of 1. The values of concentration and induction magnitude were analyzed using a PRISM 2.01 (GraphPad Software Inc., U.S.A.) to cal- culate the EC 50 , the effective concentration of test compound required to induce 50% of the maximum activity.
(b) Glucose and Lipid Lowering Experiments
The glucose and lipid lowering activities of the compounds were tested using KKA y mice. 37) After being fed a powdered laboratory chow (CE-2, Clea Japan, Inc., Tokyo, Japan) over 3 d, female mice (9-13 weeks old) were divided into experimental groups of five animals each based on their blood glucose levels. The test compounds were given as a dietary admixture at 0.01 or 0.001% in the diet. The mice were fed the experimental diet and water ad libitum for 4 d. Blood samples were taken from the orbital vein. The plasma glucose levels were determined enzymatically using Iatrochem-GLU(A) (Iatron Laboratories, Inc., Tokyo, Japan) or L type Wako Glu 2 (Wako Pure Chemical Ind., Ltd., Tokyo, Japan). The plasma triglyceride levels were also determined enzymatically using Iatro-MA701 TG kits (Iatron Laboratories, Inc.) or L type Wako TG · H (Wako Pure Chemical Ind., Ltd. 
(b) Analysis of Plasma Samples (i) Sample Preparation: Acetonitrile was added to each plasma sample (100 ml). The mixture was stirred by irradiation with supersonic waves before centrifugal separation was carried out. The supernatant liquid was subjected to centrifugal condensation under reduced pressure at 30°C. The residue was dissolved in acetonitrile-0.01 mol/l ammonium acetate (60 : 40, v/v, 200 ml). The mixture was stirred by irradiation with supersonic waves. Then centrifugal separation was carried out to remove insoluble substances. The supernatant liquid was used for HPLC analysis.
(ii) HPLC Assay: Inertsil ODS-3 (f4.6ϫ250 mm) was used for HPLC analysis. Analyses of compounds were carried out using acetonitrile-0.01 mol/l ammonium acetate (60 : 40, v/v) as a mobile phase at a flow rate of 1.0 ml/min at 40°C, and the detection wavelength was 270 nm. Under these conditions, the retention time for 27 was 14. , N-hydroxyphthalimide (2.59 g, 15.9 mmol), potassium carbonate (4.40 g, 31.9 mmol), and N,N-dimethylformamide (DMF) (50 ml) was stirred at room temperature for 20 h, then diluted with water (500 ml). The crystals were collected by filtration, washed with water, and dried under reduced pressure to give N-{4- [(5-methyl-2-phenyl-1,3-oxazol-4- (c) A mixture of 4-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]benzyloxyamine (10a, 1.00 g, 3.22 mmol), ethyl benzoylacetate (11a, 0.612 ml, 3.54 mmol), acetic acid (0.554 ml, 9.67 mmol), sodium acetate (528 mg, 6.44 mmol), and EtOH (20 ml) was refluxed for 12 h. The reaction mixture was diluted with 1 M HCl and extracted with AcOEt. The extract was washed with brine, dried over magnesium sulfate, and concentrated in vacuo. The residue was chromatographed on silica gel with AcOEt-hexane (1 : 
39 mmol) was dissolved in THF (60 ml)-water (40 ml), then lithium hydroxide monohydrate (402 mg, 9.58 mmol) was added to the mixture. The whole was stirred at room temperature for 18 h. The solution was made acidic by addition of dil. HCl and extracted with AcOEt. The extract was washed with brine, dried over magnesium sulfate, and concentrated in vacuo to give 26 (1.08 g, 99%) as crystals. Recrystallization from AcOEt-hexane gave colorless crystals. mp 107-108°C (dec.). The mixture was stirred at that temperature for 2 h. The solution was acidified with 1 M HCl, then made basic by addition of aqueous sodium hydrogen carbonate, and extracted with AcOEt. The extract was washed with brine, dried over magnesium sulfate, and concentrated in vacuo. The residue was chromatographed on silica gel with AcOEt-hexane (1 : 3, v/v) to leave an oil. The oil was dissolved in THF (100 ml)-MeOH (50 ml), then 2 M NaOH (50 ml) was added to the mixture. The whole was stirred at room temperature for 2 h, then made acidic by addition of 1 M HCl (101 ml) and extracted with AcOEt. The extract was washed with brine, dried over magnesium sulfate, and concentrated in vacuo to give crystals, which were recrystallized from AcOEt-hexane to give 27 (24.5 g, 86%) as colorless crystals (A form): mp 126-127°C. The data of powder X-ray crystal diffraction of 27 A form are shown in Table 6 .
A part of these crystals were recrystallized again from EtOH to give colorless crystals (B form Table 7 .
( (c) Thionyl chloride (1.69 g, 14.2 mmol) was added to a solution of 2-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]benzyl alcohol (5b, 4.00 g, 13.5 mmol) in toluene (60 ml), and the mixture was stirred at room temperature for 0.5 h. To the mixture was added ice-cooled water and extracted with AcOEt. The extract was washed with ice-cooled brine, dried over magnesium sulfate, and concentrated in vacuo to give 4-{[2-(chloromethyl)phenoxy]methyl}-5-methyl-2-phenyl-1,3-oxazole (6c, 3.50 g, 82%) as crystals. Recrystallization from AcOEt-hexane gave colorless crystals. mp 103-104°C. 1 (
E)-4-{3-[(5-Methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]benzyloxyimino}-2-phenylbutyric Acid (29)
(phenylpentanoate (11c, 8.00 g, 36.3 mmol), hydroxylamine hydrochloride (3
E)-9-{4-[(5-Methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]benzyloxyimino}-9-phenylnonanoic Acid (36)
A mixture of 4-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]benzyloxyamine (500 mg, 1.61 mmol), methyl 9-oxo-9-phenylnonanoate (11g, 464 mg, 1.77 mmol), sodium acetate (264 mg, 3.22 mmol), 1 M HCl (3 ml), and EtOH (20 ml) was refluxed for 72 h. The mixture was diluted with AcOEt, washed with water and brine, dried over magnesium sulfate, and concentrated in vacuo. The residue was chromatographed on silica gel with AcOEt-hexane (1 : 6, v/v) to leave an oil. The oil was dissolved in THF (10 ml)-MeOH (5 ml), then 1 M NaOH (5 ml) was added to the mixture. The whole was stirred at room temperature for 1 h, then made acidic by addition of dil. HCl and extracted with AcOEt. The extract was washed with brine, dried over magnesium sulfate, and concentrated in vacuo. The residue was recrystallized from AcOEt-hexane to give 36 (323 mg, 37%) as colorless crystals. mp 67-68°C. 1 (
E)-4-(4-Fluorophenyl)-4-{4-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]benzyloxyimino}butyric Acid (37) (a)
Ethyl succinyl chloride (40.8 ml, 286 mmol) was added dropwise to a suspension of aluminum chloride (41.6 g, 312 mmol) in 1,2-dichloroethane (300 ml) at 0°C, and the mixture was stirred at 0°C for 0.5 h. To this was added 4-fluorobenzene (25.0 g, 260 mmol). The whole was stirred at 60°C for 15 h, then poured onto ice (500g). After stirring at room temperature for 1 h, the organic layer was separated, washed with brine, dried over magnesium sulfate, and concentrated in vacuo to leave an oil. The oil was dissolved in EtOH (300 ml), then hydroxylamine hydrochloride (21.7 g, 312 mmol) and sodium acetate (32.0 g, 390 mmol) were added. The whole was refluxed for 20 h. After evaporation of the solvent, the residue was dissolved in water and extracted with AcOEt. The extract was washed with brine, dried over magnesium sulfate, and concentrated in vacuo. The residue was chromatographed on silica gel with AcOEt-hexane (1 : (
E)-4-{4-[(5-Methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]benzyloxyimino}-4-(4-phenoxyphenyl)butyric Acid (38) (a)
Ethyl succinyl chloride (14.3 ml, 100 mmol) was added dropwise to a suspension of aluminum chloride (14.7 g, 110 mmol) in CH 2 Cl 2 (120 ml) at 0°C, and the mixture was stirred at 0°C for 0.5 h. The mixture was added dropwise to a solution of diphenylether (34.0 g, 200 mmol) in CH 2 Cl 2 (50 ml) at 0°C. The whole was stirred at 0°C for 3 h, then poured onto ice (200 g). After stirring at room temperature for 1 h, the organic layer was separated, washed with brine, dried over magnesium sulfate, and concentrated in vacuo to leave an oil. The oil was dissolved in EtOH (150 ml), then hydroxylamine hydrochloride (8.34 g, 120 mmol) and sodium acetate (12.3 g, 150 mmol) were added. The whole was refluxed for 15 h. After evaporation of the solvent, the residue was dissolved in water and extracted with AcOEt. The extract was washed with brine, dried over magnesium sulfate, and concentrated in vacuo. 6 mmol) in THF (200 ml) at 0°C. The mixture was stirred at 0°C for 0.5 h and at room temperature for additional 2 h. This solution was added dropwise to a precooled (Ϫ78°C) solution of tert-butyl lithioacetate, obtained from tert-butyl acetate (17.5 ml, 130 mmol) and LDA (130 mmol) at Ϫ78°C, in THF (100 ml) over 1 h under nitrogen. After the reaction temperature was kept at this temperature for 15 min, it was quenched by addition of 1 M HCl (250 ml) and extracted with AcOEt. The extract was washed with brine, dried over magnesium sulfate, and concentrated in vacuo. The residue was chromatographed on silica gel with AcOEt-hexane (1 : 4, v/v) to leave an oil. The oil was dissolved in THF (100 ml), cooled to 0°C, then sodium hydride (60% in oil, 1.06 g, 26.4 mmol) was added. The mixture was stirred at 0°C for 10 min, then ethyl bromoacetate (2.00 ml, 18.0 mmol) was added in one portion, and the whole was stirred at 0°C for 8 h. After addition of 0.1 M HCl (300 ml) and extraction with AcOEt, the extract was washed with brine, dried over magnesium sulfate, and concentrated in vacuo. The residue was chromatographed on silica gel with AcOEt-hexane (1 : 5, v/v) to leave an oil. The oil was dissolved in toluene (200 ml) and treated with p-toluenesulfonic acid monohydrate (2.00 g, 10.5 mmol) at 80°C for 20 h. After cooling to room temperature, the solution was diluted with AcOEt, washed with saturated aqueous sodium hydrogen carbonate and brine, dried over magnesium sulfate, and concentrated in vacuo. The residue was chromatographed on silica gel with AcOEt-hexane (1 : -2-phenyl-1,3-oxazol-4-yl) methoxy]benzyloxyimino}-4-(4-pyridyl)butyric Acid (41) (a) Using the procedure for preparation of 39, step a, ethyl 4-oxo-4-(4-pyridyl)butyrate (11j, 31% yield) was prepared from 4-pyridinecarboxylic acid as a pale-brown oil. 1 benzyloxyimino}-2-phenylacetoamido)propionate (24, 720 mg, 1.33 mmol) was dissolved in THF (6 ml), water (4 ml), and MeOH (4 ml), then lithium hydroxide monohydrate (167 mg, 3.99 mmol) was added. The whole was stirred at room temperature for 1.5 h, then made acidic by addition of 1 M HCl (4.1 ml) and extracted with AcOEt. The extract was washed with brine, dried over magnesium sulfate, and concentrated in vacuo. The residue was recrystallized from AcOEt-hexane to give 42 (661 mg, 97%) as colorless crystals. mp 121-122°C. (25) (b) Methanesulfonyl chloride (1.81 ml, 23.4 mmol) was added to a solution of 2-(3-hydroxypropyl)-2-phenyl-1,3-dioxolane (22, 3.75 g, 18.0 mmol) and triethylamine (5.05 ml, 36.0 mmol) in AcOEt (100 ml) at 0°C. The mixture was stirred for 0.5 h, then washed with brine, dried over magnesium sulfate, and concentrated in vacuo to leave an oil. The oil was dissolved in acetone (100 ml), then sodium iodide (5.40 g, 36.0 mmol) was added to the solution. The whole was stirred at 60°C for 2 h. After evaporation of the solvent, the residue was dissolved in water and extracted with AcOEt. The extract was washed with brine, dried over magnesium sulfate, and concentrated in vacuo to give 2-(3-iodopropyl)-2-phenyl-1,3-dioxolane (23, 5.41 (c) n-Butyllithium (1.6 M solution in hexane, 2.16 ml, 3.46 mmol) was added dropwise to a cold (Ϫ20°C) stirred solution of diisopropylamine (0.529 ml, 3.77 mmol) in THF (5 ml), and the mixture was stirred for 20 min. The mixture was cooled to Ϫ78°C, and a THF (5 ml) solution of methyl isobutyrate (0.397 ml, 3.46 mmol) was added dropwise over a period of 0.5 h. The whole was stirred at Ϫ78°C for 20 min, then 2-(3-iodopropyl)-2-phenyl-1,3-dioxolane (23, 1.00 g, 3.14 mmol) and HMPA (0.602 ml, 3.46 mmol) were added. The mixture was stirred at Ϫ40°C for 3 h. The reaction was quenched by addition of dil. HCl and extracted with AcOEt. The extract was washed with brine, dried over magnesium sulfate, and concentrated in vacuo to leave an oil. The oil was dissolved in acetone (30 ml), then 1 M H 2 SO 4 (10 ml) was added to the solution. The whole was refluxed for 3 h, then diluted with AcOEt, washed with water, brine, dried over magnesium sulfate, and concentrated in vacuo. The residue was chromatographed on silica gel with AcOEt-hexane (1 : 7, v/v) to give methyl 2,2-dimethyl-6-oxo-6-phenylhexanoate (11k, 350 mg, 45%) as a colorless oil. (e) Methyl (E)-2,2-dimethyl-6-{4-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]benzyloxyimino}-6-phenylhexanoate (340 mg, 0.629 mmol) was dissolved in THF (5 ml)-MeOH (5 ml), then 4 M KOH (5 ml) was added. The whole was refluxed for 1.5 h. After cooling to room temperature, the mixture was made acidic by addition of dil. HCl and extracted with AcOEt. The extract was washed with brine, dried over magnesium sulfate, and concentrated in vacuo. The residue was chromatographed on silica gel with AcOEthexane (1 : 1, v/v) to give 44 (275 mg, 83%) as crystals. Recrystallization from AcOEt-hexane gave colorless crystals. mp 111-112°C. 1 2-phenyl-1,3-oxazol-4-yl) methoxy]benzyloxyimino}butyric Acid (46) (a) Chloromethyl methyl ether (34.2 ml, 450 mmol) was added dropwise to a cold (0°C) stirred suspension of 4-hydroxybenzaldehyde (50.0 g, 409 mmol), potassium carbonate (84.9 g, 614 mmol), and DMF (150 ml). The whole was stirred at 0°C for 1 h and at room temperature for additional 11 h, then diluted with water and extracted with AcOEt. The extract was washed with brine, dried over magnesium sulfate, and concentrated in vacuo to leave an oil. The oil was dissolved in THF (300 ml) and MeOH (50 ml). The solution was cooled to 0°C, then sodium borohydride (7.76 g, 205 mmol) was added portionwise. The whole was stirred at 0°C for 0.5 h, then quenched by addition of water carefully and extracted with AcOEt. The extract was washed with brine, dried over magnesium sulfate, and concentrated in vacuo. The residue was chromatographed on silica gel with AcOEt-hexane (2 : 3, v/v) to give 4-(methoxymethoxy)-benzyl alcohol (14a, 56.7 g, 82%) as a colorless oil. 1 (b) Diethyl azodicarboxylate (40% in toluene, 142 g, 325 mmol) was added dropwise to a stirred solution of 4-(methoxymethoxy)benzyl alcohol (14a, 50.0 g, 297 mmol), N-hydroxyphthalimide (44.1 g, 270 mmol), and triphenylphosphine (83.7 g, 319 mmol) in THF (900 ml) at room temperature under nitrogen. The reaction was completed within 1 h. After evaporation of the solvent, the residue was chromatographed on silica gel with AcOEthexane (1 : 1, v/v) to remove triphenylphosphine oxide. The obtained crystals were washed with solvent (AcOEt : hexaneϭ1 : 5). The crystals were dissolved in EtOH (50 ml) and THF (200 ml), then hydrazine monohydrate (33.7 ml, 694 mmol) was added dropwise. The whole was refluxed for 3 h, then cooled to room temperature, diluted with aqueous potassium carbonate and extracted with AcOEt. The extract was washed with brine, dried over magnesium sulfate, and concentrated in vacuo. To the residue was added cold (0°C) isoPr 2 O, and the crystals were removed by filtration. The filtrate was concentrated in vacuo to give crude [4-(methoxymethoxy) 7 mmol), acetic acid (5.10 ml, 89.1 mmol), sodium acetate (4.87 g, 59.4 mmol), and MeOH (200 ml) was refluxed for 15 h. After evaporation of the half of the solvent, the mixture was diluted with AcOEt, washed with dil. HCl, brine, dried over magnesium sulfate, and concentrated in vacuo to leave an oil. The oil was dissolved in MeOH (5 ml) and THF (50 ml), then 1 M HCl (10 ml) was added. The whole was refluxed for 3 h. After cooling to room temperature, the mixture was diluted with water and extracted with AcOEt. The extract was washed with brine, dried over magnesium sulfate, and concentrated in vacuo. The residue was chromatographed on silica gel with AcOEthexane (2 : 5, v/v) to give methyl (E)-4-[(4-hydroxybenzyloxy)imino]-4-phenylbutyrate (17a, 4.24 g, 50%) as a colorless oil. 
